There is provided a method for treating or reducing the effects of fructose intolerance and health problems associated with excessive fructose intake by administration of glucose isomerase. Other embodiments are also disclosed.

The present invention relates to a genetically engineered yeast capable of manufacturing a fermentation product using sucrose as a fermentation substrate, and fermentation processes using such a yeast. The yeast has an exogenous invertase gene and has a deletion or disruption of the PDC activity gene. Accordingly, the yeast is useful for manufacturing fermentation products other than ethanol from fermentation substrates containing sucrose.

The invention relates to a genetically modified microorganism for making a oligosaccharide, preferably of 3-8 monosaccharide units, more preferably of 3-5 monosaccharide units, particularly a HMO, which comprises one or more genes encoding a sucrose utilization system, so the microorganism can use sucrose as a carbon and energy source.

The present invention relates to recombinant cells and microorganisms of the phylum Labyrinthulomycota and their use in heterologous protein production. Novel promoter, terminator, and signal sequences for efficient production and, optionally, secretion of polypeptides from recombinant host cells and microorganisms are also encompassed by the present invention.

The present invention is related to an enzyme that allows efficient removal of fructan from grain and vegetable raw material. The enzyme according to the invention produces grain and vegetable material having a fructan content significantly lower compared to that of the starting material.

Disclosed are compositions and methods useful for improving blood cholesterol profiles in a mammal, particularly for improving metabolism of cholesterol, for reducing the levels of low-density lipoprotein cholesterol (LDL-C) in the blood, increasing the levels of high-density lipoprotein (HDL-C) in the blood, for improving weight loss in a mammal, and/or for enhancing overall cardiovascular health in a mammal. Methods can involve identifying a mammal in need of lowering of blood LDL-C and/or triglyceride concentrations, and administering to said mammal a specific formulation consisting of a blend of probiotics; specifically, Bifidobacterium infantis, Bifidobacterium bifidum, Lactobacillus acidophilus, Lactobacillus salivarius, Lactobacillus plantarum, Lactobacillus rhamnosus, Bifidobacterium longum, Lactobacillus casei, Lactobacillus paracasei, in combination with a blend of digestive enzymes; specifically, amylase, glucoamylase, lipase, bromelain, maltase, lactase, hemicellulase, xylanase, papain, and invertase. Preferably, the aforementioned probiotics and digestive enzymes are combined into capsules and administered to said mammal three times daily to achieve said lowering of LDL-C and triglyceride concentrations in blood.

Described are methods for generating a reporter molecule in response to a target analyte in a cell-free system. A synthetic biological circuit is used to modify the level of the reporter molecule in response to the presence of the target analyte. The reporter molecule may be glucose or another molecule readily detected using a device such as glucose monitor or other portable sensor. Also provided are kits comprising a cell-free system with a synthetic biological circuit that generates or consumes a reporter molecule in response to a target analyte.

The present invention is related to an enzyme that allows efficient removal of fructan from grain and vegetable raw material. The enzyme according to the invention produces grain and vegetable material having a fructan content significantly lower compared to that of the starting material.

The present invention relates to a genetically engineered yeast capable of manufacturing a fermentation product using sucrose as a fermentation substrate, and fermentation processes using such a yeast. In some embodiments, the fermentation product is ethanol.

The invention relates to a genetically modified microorganism for making a recombinant oligosaccharide, preferably of 3-8 monosaccharide units, more preferably of 3-5 monosaccharide units, particularly a HMO, which comprises one or more genes encoding a sucrose utilization system, so the microorganism can use sucrose as a carbon and energy source. The one or more genes encoding a sucrose utilization system are preferably one or more genes encoding a heterologous PTS-dependent sucrose utilization transport system, such as the scr genes.